Notably, patients with high MET expression (MET3+ expression in ≥90% of tumor cells; n = 24) revealed a significant improvement in PFS, with EMI + E showing a median PFS of 20.7 months compared to 5.4 months for E, suggesting that high-MET patients may receive clinically meaningful benefits from emibetuzumab and erlotinib. The gene discussed is MET; the disease is neoplasm.